Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TT-034 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Escalating Dose of TT-034 | EXPERIMENTAL | The study contains one dose escalation arm with active drug. |
| Name | Type | Description |
|---|---|---|
| TT-034 | DRUG | The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given. |
Inclusion Criteria: Subjects must a history of chronic HCV infection defined as documented HCV genotype 1 infection for at least 6 months. * Subjects must have: 1. Documented failure to respond to prior treatment or relapse with a combination of peg-interferon (peg-IFN), ribavirin (RBV), and ei...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir |
TT-034 is an investigational small molecule developed by Benitec Biopharma Inc. for the treatment of chronic hepatitis C. It was studied in a single Phase 1 clinical trial and is not an approved therapy. The program was evaluated in patients with chronic hepatitis C virus infection in the United States.
TT-034 was being developed as a treatment for chronic hepatitis C, an infectious disease of the liver caused by the hepatitis C virus. Its only clinical study enrolled patients with chronic hepatitis C to assess safety and efficacy of single doses. It is investigational and has not been approved for any use.
TT-034 is developed by Benitec Biopharma Inc., which trades under the ticker BNTC. The company sponsored the Phase 1 study of the drug in patients with chronic hepatitis C. Benitec Biopharma is the sole developer named for this asset.
TT-034 is in Phase 1 development. It has completed one Phase 1 clinical trial and has no active trials. The drug is investigational and has not been approved by the FDA or any other regulatory agency for the treatment of hepatitis C.
TT-034 was evaluated in one completed Phase 1 trial, NCT01899092, titled Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C. The study enrolled 9 patients aged 18 years and older in the United States. It was an uncontrolled, non-randomized, open-label study.